Cysteine metabolic engineering and selective disulfide reduction produce superior antibody-drug-conjugates

Next-generation site-specific cysteine-based antibody–drug-conjugates (ADCs) broaden therapeutic index by precise drug-antibody attachments. However, manufacturing such ADCs for clinical validation requires complex full reduction and reoxidation processes, impacting product quality. To overcome this...

Descripción completa

Detalles Bibliográficos
Autores principales: Procopio-Melino, Renée, Kotch, Frank W., Prashad, Amar S., Gomes, Jose M., Wang, Wenge, Arve, Bo, Dawdy, Andrew, Chen, Lawrence, Sperry, Justin, Hosselet, Christine, He, Tao, Kriz, Ronald, Lin, Laura, Marquette, Kimberly, Tchistiakova, Lioudmila, Somers, Will, Rouse, Jason C., Zhong, Xiaotian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068625/
https://www.ncbi.nlm.nih.gov/pubmed/35508689
http://dx.doi.org/10.1038/s41598-022-11344-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068625/
https://www.ncbi.nlm.nih.gov/pubmed/35508689
http://dx.doi.org/10.1038/s41598-022-11344-z

Ejemplares similares